kabutan

DAIICHI SANKYO COMPANY, LIMITED(4568) Summary

4568
TSE Prime
DAIICHI SANKYO COMPANY, LIMITED
2,650.5
JPY
+48.0
(+1.84%)
Apr 28, 3:30 pm JST
16.64
USD
Apr 28, 2:30 am EDT
Result
PTS
outside of trading hours
2,645
Apr 28, 11:28 pm JST
Summary Chart Historical News Financial Result
PER
16.7
PBR
2.82
Yield
2.94%
Margin Trading Ratio
13.74
Stock Price
Apr 28, 2026
Opening Apr 28, 9:00 am
2,606.0 JPY 16.35 USD
Previous Close Apr 27
2,602.5 JPY 16.32 USD
High Apr 28, 3:24 pm
2,670.0 JPY 16.76 USD
Low Apr 28, 9:01 am
2,545.5 JPY 15.97 USD
Volume
13,321,300
Trading Value
0.03T JPY 0.22B USD
VWAP
2622.08 JPY 16.47 USD
Minimum Trading Value
265,050 JPY 1,664 USD
Market Cap
5.02T JPY 0.03T USD
Number of Trades
19,293
Liquidity & Number of Trades
As of Apr 28, 2026
Liquidity
High
1-Year Average
9,795
1-Year High Jan 30, 2026
50,451
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 179,600 9,656,700 53.77
Apr 17, 2026 200,400 8,066,000 40.25
Apr 10, 2026 146,500 8,670,100 59.18
Apr 3, 2026 169,500 8,057,200 47.54
Mar 27, 2026 370,300 8,083,600 21.83
Company Profile
DAIICHI SANKYO COMPANY, LIMITED is a major pharmaceutical company in Japan, with strengths in cardiovascular and infectious diseases. The company has partnered with AstraZeneca of the UK for new cancer drugs.
Sector
Pharmaceuticals
DAIICHI SANKYO COMPANY, LIMITED primarily engages in the research, development, manufacturing, and sales of pharmaceuticals, with a broad range of operations both domestically and internationally. In Japan, the company operates through multiple subsidiaries involved in pharmaceutical manufacturing, research and development and sales of over-the-counter drugs, and vaccine research, development, and production, showcasing a diverse group of companies with varied functions. The company has partnered with AstraZeneca in the oncology field. Internationally, DAIICHI SANKYO has subsidiaries in the United States, Europe, China, Brazil, and other regions, conducting pharmaceutical research, development, manufacturing, and sales in each area. In the United States, the company has established a holding company, while in Europe, it operates through numerous group companies across various countries. DAIICHI SANKYO leverages its global network for research, development, manufacturing, and sales to enhance its competitiveness in the world market.